Kidney and urologic disease status update: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 493: Line 493:
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
! rowspan="1" style="background: #4479BA; padding: 5px 5px;" |{{fontcolor|#FFFFFF|Reviewer name}}
|-
|-
| rowspan="30" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Kidney diseases
| rowspan="22" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |Kidney diseases
| style="padding: 5px 5px; background: #F5F5F5;" |Electrolyte imbalance (LP)
| style="padding: 5px 5px; background: #F5F5F5;" |Electrolyte imbalance (LP)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 670: Line 670:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Beta-2 microglobulin related amyloidosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |Gelsolin related amyloidosis
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 728: Line 679:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |

Revision as of 13:09, 7 July 2020

System leader: Maneesha Nandimandalam, MD

List of Chapters Requiring Content

Category Chapters that need content Assignment Status Scholar's name Coach name Completion Status Review status Reviewer name
Kidney diseases
  • Abderhalden-Kaufmann-Lignac syndrome
  • Analgesic nephropathy
 Assigned Shakiba Elsaiey, Ahmed
  • Balkan nephropathy
  • Continuous veno-venous hemofiltration
  • Contrast-induced acute kidney injury
  • Dent's disease
  • Dialysis (LP)
  • Diuresis
  • Fibrillary immunotactoid glomerulopathy
  • Haff disease
  • Hemodialysis (SP)
  • HIV associated nephropathy
 Assigned Shakiba Elsaiey,Ahmed Completed
  • Hypertensive nephropathy
 Assigned Nasrin Elsaiey,Ahmed
  • Kidney transplantation
  • Milk-alkali syndrome
  • Multicystic dysplastic kidney
  • Nephroptosis
  • Nutcracker syndrome
  • Papillorenal syndrome
  • Peritoneal dialysis (SP)
  • Phosphate nephropathy
 Assingned Ayesha FJ Sogand
  • Rhabdomyolysis
 Assingned Ayesha FJ, Sogand

In progress chapters

Category Chapters that need content Assignment Status Scholar's name Coach name Completion Status Review status Reviewer name
Kidney diseases Cardiorenal syndrome Assigned Dina Huda

Completed chapters

Category Chapters that need content Assignment Status Scholar's name Coach name Completion Status Review status Reviewer name
Kidney diseases Electrolyte imbalance (LP)
Hyponatremia
Hypernatremia
Hypokalemia
Hyperkalemia
Hypocalcemia
Hypercalcemia
Glomerular Disease(LP)
Lupus Nephritis
Rapidly progressive glomerulonephritis
Membranous glomerulonephritis
Membranoproliferative glomerulonephritis
IgA nephropathy
Goodpastures syndrome
Amyloidosis (LP)
Primary amyloidosis
Secondary amyloidosis
Familial amyloidosis
Wild-type(senile) amyloidosis
Cardiac amyloidosis
Retrieved from "https://www.wikidoc.org/index.php?title=Kidney_and_urologic_disease_status_update&oldid=1622062"